Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
AirJoule Technologies 4Q/Full Year 2025 Earnings Call - Built the commercialization foundation, 2026 is execution year
AirJoule spent 2025 building hardware, partnerships, and field proof points, and the company says 2026 is when those investments must start producing commercial pipeline and revenue. The year closed w...
- 2025 was a foundational year; AirJoule moved from lab demos to multiple field deployments and says 2026 is when it will convert that work into a commercial pipeline.
- Field validation occurred in Texas (Hubbard), Arizona (ASU independent evaluation), California (Pescadero pilot with Red Dot Ranch), and Dubai, providing months of operational data across varied climates.
- Product branding and roadmap: A250 is now AirJoule Core, A1000 is AirJoule Prime; Core is a two-chamber system and Prime is the larger industrial-scale unit.
- +12 more takeaways
LENSAR Q4 2025 Earnings Call - Merger Terminated, ALLY Validated, Company Reboots as Standalone
LENSAR closed 2025 with clear scars and a usable blueprint. The planned Alcon acquisition was terminated after FTC resistance, but management frames the process as a market validation for the ALLY rob...
- Acquisition with Alcon was terminated after the FTC signaled it would seek to enjoin the merger, the decision described as mutual and pragmatic.
- Management argues the Alcon process validated the ALLY Robotic Cataract Laser System as superior to first-generation femto lasers, reinforcing product value.
- LENSAR received the $10 million transaction deposit from escrow, and reported cash at December 31 of $18 million which will be cleared of the $10 million deposit liability in Q1 2026.
- +13 more takeaways
McCormick & Company Q1 Fiscal 2026 Earnings Call - McCormick to Combine with Unilever Foods, Creating a $20B Flavor Powerhouse with $600M Synergies
McCormick used its quarterly call to unveil a transformational combination with Unilever Foods, structured as a Reverse Morris Trust that will leave the combined company with roughly $20 billion in pr...
- Deal announced: McCormick will combine with Unilever Foods in a Reverse Morris Trust style transaction, prioritizing the carve-out and strategic integration over the Q1 earnings review.
- Ownership and consideration: Unilever and its shareholders will own ~65% of the combined company, McCormick shareholders ~35%, and Unilever will receive $15.7 billion in cash as part of the transaction.
- Valuation and multiple: Transaction implies an enterprise value for Unilever Foods of about $44.8 billion, with the deal priced at roughly 13.8x calendar 2025 EBITDA, parity with McCormick.
- +12 more takeaways
Purple Innovation Q4 2025 Earnings Call - Premium Products and Wholesale Drive Return to Profitability
Purple closed 2025 with a tangible operational turn. Q4 revenue accelerated to $140.7 million, adjusted EBITDA swung to a positive $8.8 million for the quarter and the company finished the year modest...
- Q4 revenue was $140.7 million, up approximately 9.1% year-over-year, driven primarily by wholesale.
- Full-year 2025 revenue was $468.7 million, down about 3.9% versus 2024, reflecting a soft e-commerce year offset by wholesale and showroom gains.
- Adjusted EBITDA was $8.8 million in Q4 and $1.9 million for full-year 2025, a material improvement from the prior year.
- +12 more takeaways
TON Strategy Company Full Year 2025 Earnings Call - Staked Treasury Live, 219.7M TON Staked and $114.2M Crypto Reval Loss
TON Strategy Company spent 2025 building the plumbing for a simple promise, hold Toncoin, stake a large share, and grow TON per share inside a public company. The team launched staking in August, and ...
- Staking is live and material: 219.7 million TON were staked at year-end after staking began in August 2025.
- Staking produced 2.19 million TON in rewards since implementation, contributing roughly $4 million to 2025 revenue.
- Total revenue for 2025 rose to $12.8 million, up from $0.9 million in 2024, with staking part of that lift.
- +12 more takeaways
Prairie Operating Co. Year-End 2025 Earnings Call - Bayswater Integration Boosts Scale, Capital-Structure Remains the Real Overhang
Prairie spent 2025 bulking up and proving it can run a bigger company. The Bayswater acquisition closed and was fully integrated, plus five bolt-ons expanded the DJ Basin footprint to roughly 44,000 i...
- Prairie completed full integration of Bayswater assets and executed six transactions in 2025, adding approximately 44,000 net acres inclusive of Bayswater.
- Reported full-year production was ~6.75 million BOE (avg ~18,500 BOE/day); including pro forma Bayswater first-quarter volumes, full-year production would be ~24,000 BOE/day, roughly 4x YoY; exit rate was ~28,000 net BOE/day.
- Total revenue for 2025 was approximately $242 million, or ~$315 million inclusive of Bayswater pro forma contribution.
- +13 more takeaways
AlTi Q4 2025 Earnings Call - CEO Transition, Incentive Fees and ZBB Set Stage for 2026 Turning Point
AlTi closed 2025 with solid top-line momentum but a noisy income statement. Assets under management hit $50 billion, driving total revenue of $255 million, up 29% year-over-year, and adjusted EBITDA o...
- Leadership change: Founder and CEO Michael Tiedemann is stepping down after more than 25 years, Nancy Curtin (Global CIO) named Interim CEO.
- AUM reached $50 billion at year-end 2025, up 10% year-over-year, driven by investment performance and the Kontora acquisition.
- Total revenue for 2025 was $255 million, a 29% increase versus 2024, with recurring management fees near $200 million.
- +11 more takeaways
Solésence Q4 2025 Earnings Call - Transform and Transcend plan prioritizes operational fixes to restore margins
Solésence closed 2025 with record revenue of $62.1 million, up 18.6% year over year, but growth came with painful execution costs. Q4 revenue held roughly flat at $12.5 million, gross margin improved ...
- Full year 2025 revenue reached a record $62.1 million, up 18.6% from $51.9 million in 2024, driven by a large-scale launch and 20 new brand partners.
- Q4 2025 revenue was $12.5 million, roughly flat year over year; Q4 gross profit improved to $3.4 million from $2.8 million, with gross margin at 27% versus 22% in Q4 2024.
- Full-year gross profit finished essentially flat at $16.1 million versus $16.2 million in 2024, showing that top-line growth did not translate into higher annual gross profit.
- +12 more takeaways
B.O.S. Better Online Solutions Ltd. Full Year 2025 Earnings Call - Record 2025, Conservative 2026 Guidance Despite $24M Backlog
B.O.S. closed 2025 with clear momentum, reporting record revenue of $51.0 million, up 27% year-over-year, and net income of $3.6 million, up 57%. Management points to a healthy $24 million contracted ...
- Record 2025 results: revenues $51.0M, up 27% YoY; net income $3.6M, up 57% YoY.
- Contracted backlog of $24M at year-end 2025, covering about 50% of 2026 guidance and giving visibility into revenue.
- Management issued conservative 2026 guidance equal to 2025: ~ $51M revenue and ~$3.6M net income, with upgrades expected quarterly if momentum continues.
- +14 more takeaways
MiNK Therapeutics Fourth Quarter and Year-End 2025 Earnings Call - Advancing randomized ARDS trial and GVHD dosing with non-dilutive funding, clinical readouts expected in 2026
MiNK spent the call selling one clear story, clinical momentum plus capital discipline. The company positions its allogeneic iNKT platform as off-the-shelf, steroid-resistant, and safe, with durable s...
- Platform and differentiation: MiNK advances an allogeneic invariant natural killer T cell, off-the-shelf platform that is administered without lymphodepletion or HLA matching, and management emphasizes a favorable safety profile.
- Durability signal in oncology: In checkpoint-refractory solid tumors, MiNK reported median overall survival exceeding 23 months in combination with PD-1 therapies, and complete remissions beyond two years in heavily pretreated patients.
- Mechanistic data: Clinical and translational readouts show coordinated immune effects, including dendritic cell activation, macrophage repolarization, reinvigoration of exhausted T cells, and controlled increases in IFN gamma, IL-2 and TNF alpha consistent with productive response without systemic toxicity.
- +12 more takeaways